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Inferring molecular networks can reveal how genetic
perturbations interact with environmental factors to
cause common complex diseases. We analyzed ge-
netic and gene expression data from seven tissues
relevant to coronary artery disease (CAD) and identi-
fied regulatory gene networks (RGNs) and their key
drivers. By integrating data from genome-wide asso-
ciation studies, we identified 30 CAD-causal RGNs
interconnected in vascular and metabolic tissues,
and we validated them with corresponding data
from the Hybrid Mouse Diversity Panel. As proof of
concept, by targeting the key drivers AIP, DRAP1,
POLR2I, and PQBP1 in a cross-species-validated,
arterial-wall RGN involving RNA-processing genes,
we re-identified this RGN in THP-1 foam cells and in-
dependent data from CAD macrophages and carotid
lesions. This characterization of the molecular land-
scape in CAD will help better define the regulation
of CAD candidate genes identified by genome-
wide association studies and is a first step toward
achieving the goals of precision medicine.
INTRODUCTION
Coronary artery disease (CAD) is a heritable complex disease
caused by the interactions of multiple genetic and environmental
risk factors that change the molecular landscape of vascular and196 Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authorsmetabolic tissues to accelerate atherosclerosis. Despite lifestyle
improvements and the successful targeting of CAD risk factors,
such as hypercholesterolemia (Samani and de Bono, 1996) and
hypertension (Bangalore et al., 2012), CAD still accounts for the
majority of cardiovascular diseases. In fact, the clinicalmanifesta-
tions of CAD and atherosclerosis—myocardial infarction (MI) and
stroke—are responsible for nearly 50% of all deaths globally
(Mensah et al., 2014). New research strategies are urgently
needed to battle CAD. One promising strategy is systems ge-
netics (Baraba´si et al., 2011; Bjo¨rkegren et al., 2015; Civelek and
Lusis, 2014; Schadt, 2009; Schadt and Bjo¨rkegren, 2012), which
will help achieve a global understanding of how regulatory gene
networks (RGNs) act within and across tissues to cause CAD.
Suchknowledge iscentral to tailor therapies to thespecificmolec-
ular pathology of the individual patient (Collins andVarmus, 2015).
An important part of systems genetics is genome-wide asso-
ciation studies (GWASs), the predominant approach to genetic
analysis of complex diseases for the last decade, which have
led to the discovery of more than 150 genetic risk loci for CAD
alone (Deloukas et al., 2013; Peden and Farrall, 2011;). However,
these information-rich datasets have been analyzed only from
the perspective of single DNA variants and, therefore, are a
largely untapped resource to further elucidate the genetic basis
of complex diseases. We and others (Baraba´si et al., 2011; Bjo¨r-
kegren et al., 2015; Civelek and Lusis, 2014; Schadt and Bjo¨r-
kegren, 2012) propose to use systems genetics to integrate the
analyses of GWASs with functional genomic datasets where
the combined effects of many, sometimes subtle, genetic and
environmental influences are captured within molecular net-
works. In this study, we applied a systems genetics pipeline (Fig-
ures 1 and S1), including integrative multi-tissue, GWAS, and
cross-species analyses to robustly identify RGNs in CAD. In
Figure 1. Schematic Flow of Analytic Steps
(A) STAGE tissue sampling. The STAGE study was undertaken at the Karolinska University Hospital, Stockholm, Sweden. Patients eligible for coronary artery
bypass grafting were included, and sevenmetabolic and vascular tissues were biopsied during surgery. RNA samples were screenedwith Affymetrix Gene Chips
rendering expression values for 19,610 genes. DNA was screened for 909,622 SNPs (Experimental Procedures).
(B) Weighted gene co-expression network analysis (WGCNA) to generate tissue-specific and cross-tissue co-expression modules. Gene expression values
across all seven tissues were considered together to identify tissue-specific and cross-tissue co-expressionmodules. In the illustrated topological overlap matrix
(TOM, also in Figure 2A), rows and columns are genes expressed in specific tissues (i.e., the same gene may occur up to seven times), and the seven tissues are
intermixed. The diagonal indicates modules of highly co-expressed genes (Experimental Procedures).
(C) Module association with CAD phenotypes. To define modules of possible relevance for CAD, we sought both linear and nonlinear relationships between the
activity of the identified co-expression modules and four main CAD phenotypes as follows: (1) the extent of coronary atherosclerosis as assessed in preoperative
angiograms (atherosclerosis modules), (2) plasma measures of cholesterol (i.e., total, VLDL, LDL, or HDL cholesterol levels; cholesterol modules), (3) glucose
metabolism (i.e., fasting glucose, HbA1c, insulin, or pro-insulin; glucose modules), and (4) high-sensitivity C-reactive protein (CRP modules). Heatmap (left)
shows an example of how genes in a second-step clustering segregate the patients into two groups that differ phenotypically. Shown are examples of regression
plots (right) between individual eigengene values (x axis) and individual phenotypic values (y axis).
(D) Assessment of module causality with STAGE eQTLs and GWASs. Causal co-expression modules were sought by (1) assessing the associations of module
eQTLs (or of SNPs within ±500 kb of transcription start or end site if less than ten eQTLs) with CAD using CARDIoGRAM data and (2) the module contents for CAD
candidate genes identified by GWASs. The eQTLs were sought to match the tissue-specific gene expression (left); GWA genes are those mapped to regions of
genome-wide significant loci as exemplified in the Manhattan plot (right).
(E) Bayesian network reconstruction of RGNs and key driver analysis. Co-expression modules indicate correlations between genes without directions. In
contrast, inference of RGNs considers the causal roles of eQTLs, transcription factors, and CAD GWA candidate genes to construct directed gene-gene
connections. As a consequence, the hierarchical order among network genes can be determined, and the genes most essential for network regulation can be
identified in the form of key drivers.
(legend continued on next page)
Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authors 197
sum, we identified 30 CAD-causal RGNs harboring 59 CAD-
related GWA candidate genes (Deloukas et al., 2013), whereof
26 RGNs were validated in corresponding gene expression
and phenotypic data from the Hybrid Mouse Diversity Panel
(HMDP) (Bennett et al., 2010). As proof of concept, key drivers
in CAD-causal RGNs active in both the human and mouse
atherosclerotic arterial wall (AAW) were further evaluated in a
THP-1 foam cell model (Figure 1G) and in independent data
from primary CAD macrophages and carotid lesions.
RESULTS
Inference of Co-expression Network Modules
In the first step of our analysis (Figure 1), we used weighted gene
co-expression network analysis (WGCNA) (Zhang and Horvath,
2005) to infer functionally related genes in the form of co-expres-
sion modules from 612 newly generated gene expression pro-
files from seven tissues—AAW and non-AAW (internal mammary
artery [IMA]), liver, skeletal muscle (SM), visceral fat (VF), subcu-
taneous fat (SF), and whole blood from the late-stage CAD
patients of the Stockholm Atherosclerosis Gene Expression
(STAGE) study (Ha¨gg et al., 2009; Table S1; Figures 1A, 1B,
and S1). We identified 94 tissue-specific and 77 cross-tissue
modules (Figure 2A; Tables S2 and S3). The relevance of these
171 modules for CAD was reflected in the top ten biological pro-
cesses and molecular functions according to gene ontology (Ta-
ble S3; Supplemental Experimental Procedures). Moreover, we
found 2,467 genes previously related to CAD/atherosclerosis
(33%, p = 1.5 3 1024; Supplemental Experimental Procedures)
and 147 genes of 309 candidate genes proposed for risk loci
identified by GWASs (Table S4; GWA genes) for CAD (n = 33 of
53 GWA genes) (Deloukas et al., 2013), plasma lipids (n = 87 of
183), and measures of plasma glucose metabolism (n = 22
of 43), including type 2 diabetes (n = 45 of 98) (Welter et al., 2014).
To test the robustness of cross-tissue modules against the
contribution of gene expression in individual tissues, we
removed gene expression data from one tissue and re-clustered
the data. The 171 modules could largely be retrieved, except
when data from dominant tissues in cross-tissue modules
were removed (Supplemental Experimental Procedures).
Identification of Modules Associated with Main CAD
Phenotypes
In the third step of the analysis pipeline (Figures 1C and S1), we
used regression analysis and second-step clustering to identify
linear and non-linear associations betweenmodule gene expres-
sion and CAD phenotypes (Supplemental Experimental Proce-
dures). We found 61 modules that were associated with at least
one of the following fourmajor CADphenotypes: (1) extent of cor-
onary atherosclerosis as measured in preoperative angiograms(F) Cross-species validation with the HMDP. Many metabolic and vascular
validate the human RGN modules, we related gene expression in correspo
Procedures).
(G) The siRNA targeting of key drivers in THP-1 macrophages and foam cells
atherosclerosis RGNmodules in human THP-1 monocytes differentiated into THP
the network module, we used custom microarrays to assess the response in net
siRNA targeting of the key drivers also affected THP-1 foam cell formation (right).
WGCNA to THP-1 foam cells.
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plasma levels of total cholesterol (TC), very-low-density lipopro-
tein (VLDL), low-density lipoprotein (LDL), or high-density lipo-
protein (HDL) (29 cholesterol modules); (3) plasma glucose (fast-
ing), HbA1c, insulin, or pro-insulin levels (14 glucose modules);
and (4) the inflammatory marker C-reactive protein (CRP) (15
CRP modules) (Figure 2B). Ten modules were associated with
more than one of the four phenotypes (Figure 2B; Table S2).
Manual analysis of the atherosclerosis-, cholesterol-, glucose-,
and CRP-associated modules suggested that, depending on
phenotype association, themodulesweremore likely to be tissue
specific (atherosclerosis, cholesterol, and CRP modules) or
cross-tissue (glucose modules). Moreover, some modules were
associatedwithmore than one of the fourmajor CADphenotypes
(Supplemental Experimental Procedures).
Inferring Module Causality by Using GWAS of CAD
The associations between the 61 co-expression modules and the
fourCADphenotypesdonot revealwhether themodule activityal-
ters the phenotypic values (causal) or is caused by changes in
phenotypic values (reactive). Therefore, in the fourth step of our
analysis (Figures 1D andS1), we assessed if the phenotype-asso-
ciated modules were CAD causal or not. As in previous studies
(Emilsson et al., 2008; Foroughi Asl et al., 2015; Schadt and Bjo¨r-
kegren, 2012), we defined causal modules as those containing
either of the following: (1) cis-acting expression quantitative trait
loci (cis-eQTLs) (or, if a module had <10 eQTLs, cis-located
SNPs) enriched in association with CAD according to CAD
GWAS (Deloukas et al., 2013; Figure 2B, column 2); or (2) one or
more CAD candidate genes (Brænne et al., 2015) already identi-
fied for CAD GWAS risk loci (Figure 2B, column 3; Table S4).
Using these definitions, we identified 30 CAD-causal modules
(Figure 2B): eight atherosclerosis modules (of 14), ten cholesterol
modules (of 29), five glucose modules (of 14), four CRP modules
(of 15), and three additional CAD-causal modules that were
associated with more than one of the four CAD phenotypes (Fig-
ure 2B). By integrating GWASs also for CAD risk factors (Welter
et al., 2014), we found that the 30 CAD-causal modules con-
tained 59 unique GWA genes for CAD (n = 19), plasma choles-
terol (n = 39), and glucose metabolism (n = 14, including type 2
diabetes GWA genes) (Table S4) and 42% CAD/atherosclerosis
genes (p = 1.23 105). Of theCAD-causal modules, 18were also
causal for plasma cholesterol levels (n = 15) or glucose meta-
bolism (n = 12), based on their eQTL risk enrichment or the pres-
ence of GWA genes (Table S2).
Inference of RGNs and Key Drivers from the Co-
expression Modules
In the next step of the analysis (Figures 1E and S1), to define the
directions of edges between genes in the 30 CAD-causalprocesses are believed to be conserved between mice and humans. To
nding mouse tissues to corresponding mouse phenotypes (Experimental
. As proof of concept, we tested key drivers of the cross-species-validated
-1 macrophages and foam cells. First, to test key driver specificity in activating
work gene activity in THP-1 macrophages (left). Then we determined whether
(Bottom right) The same analytical flow is presented in a triangle, ranging from
Figure 2. Co-expression Modules Associated with CAD Phenotypes
(A) TOM of gene activity sorted according to co-expression within and across tissues forming co-expression modules. The TOM shows the 20% most strongly
co-expressed genes within and across tissues in 61 CAD-associated modules. Color-coded bars on the y axis and x axis indicate individual modules. The red
rectangle encompasses modules related to coronary atherosclerosis; the two green rectangles encompass the modules related to measures of plasma
cholesterol; the two blue rectangles encompass the modules related to measures of plasma glucose metabolism; and the two purple rectangles encompass the
modules related to plasma CRP. Overlapping rectangles reflect modules associated with more than one of the four main phenotypes. The yellow-red color code
(bottom right) indicates the strength of TOM associations (i.e., a weighted combination of direct co-expression and shared co-expression to other genes in the
network).
(B) The sixty-onemodules (module ID/row) were associated with the extent of coronary atherosclerosis assessed in preoperative angiograms (first column, ATH);
plasma levels of total, VLDL, LDL, and HDL cholesterol and triglycerides (second column, CHOL); fasting glucose, HbA1c, insulin, or pro-insulin levels (third
column, GLUC); and CRP level (fourth column, CRP). The module-phenotype association was assessed by second-step clustering of the STAGE patients, based
on expression of module genes, and by correlating eigengene module values for each STAGE patient with phenotypic values; red colors indicate strength of
associations (log10(P)) (Experimental Procedures). The second and third columns indicate enrichment in disease association (risk) determined from the
CARDIoGRAM dataset of module eQTLs (RISK, from 1- to 9-fold, green) and the presence of established GWA genes for CAD (GWAS, from 1–6 GWA genes,
blue), respectively. (Right) The lengths of the horizontal bars indicate module size (i.e., gene numbers); the colors indicate the tissues where the module is active.modules, we inferred RGNs including key drivers by Bayesian
network modeling, using transcription factors, eQTL genes, and
GWA genes as prior candidate regulators (Figures 3 and S2–
S5; Tables S5 and S6; Supplemental Experimental Procedures).
Of the RGNs inferred from the 30 CAD-causal modules,
eight associated with the extent of atherosclerosis (i.e.,
atherosclerosis modules) are shown in Figure 3. A nearly
SF-specific RGN related to steroid and lipid metabolism (n =
231 genes, including one liver and one AAW gene) contained
ten GWA genes identified for CAD, cholesterol, or glucose traits
(APOA1CAD,LDL,HDL,TC, ANGPTL3LDL,TC, HPRLDL,TC, LIPCHDL,TC,
LIPGHDL,TC, NPC1L1LDL,TC, PPP1R3BLDL,HDL,TC,insulin,glucose,
PROX1glucose, SLC2A2glucose, and TMEM195glucose). Of these
10 GWA genes, only APOA1 was a key driver; the other key
drivers were CYP4F2, F11, KLKB1, KMO, MYCL1, and
ZGPAT. This RGN also was highly enriched in association
with fasting glucose (8.0-fold, p < 3.3 3 10272) and TC (8.7-fold, p < 1.0 3 10300) (Figure 3A). Another truly SF-specific
RGN, related to metabolic processes and oxidore-
ductase activity (n = 195 genes), contained as many as 15
GWA genes (ABCG5LDL,CAD,TC, ABCG8LDL,CAD,TC, ANXA9LDL,
APOA5LDL,HDL,CAD,TC-TG, APOC4LDL, CPS1HDL, CYP7A1LDL,TC,
FOXA2glucose, GCKRTC,glucose,insulin, HNF1ATC,LDL, HNF1BT2DM,
LPALDL,CAD,TC, NR0B2LDL,HDL, PLGCAD, and PCSK9LDL,CAD,TC).
Again, besides PLG, the key drivers of this network were not
these GWA genes; they were FOXA2, NR1I2, ONECUT2, and
UROC1 (Figure 3B).
Three CAD-causal atherosclerosis-related RGNs (Figures 3C,
3D, and 3H) were AAWspecific. The first, an RGN (n = 131 genes)
enriched in immune system processes, contained the macro-
phage lipid and inflammatory regulators and GWA genes
APOECAD and NR1H3HDL as its key drivers, together with
CD80, E2F2, HCLS1, and PDE8B (Figure 3C). The second, an
RGN (n = 109 genes) also linked to HDL cholesterol levels,Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authors 199
contained RNA-processing genes highly enriched in CAD asso-
ciation (2.1-fold, p < 1.0 3 10300) with seven key drivers (AIP,
DRAP1, MRPL28, PCBD1, POLR2I, PQBP1, and ZNF91) and
one GWA gene (ARF5T2DM) (Figure 3D). The third AAW-specific
RGN was small (n = 31 genes), even further enriched in CAD as-
sociation (4.6-fold, p < 1.0 3 10300), and mainly contained
genes involved in inflammatory responses and the GWA gene
ADRA2Aglucose (Figure 3H).
The remaining three CAD-causal, atherosclerosis-related
RGNs contained genes from multiple tissues (Figures 3E–3G).
The first was dominated by AAW genes (n = 53/81), but it
had at least three genes active in all of the CAD-relevant tissues
except in blood. This RGN contained two GWA genes
(ABCA1HDL,TC and CETPLDL,HDL,TG-TC); was highly enriched in
association with CAD (3.8-fold, p < 8.8 3 1049), plasma tri-
glyceride levels (5.3-fold, p < 2.3 3 10103), and fasting glucose
levels (1.9-fold, p < 5.6 3 1006); and had seven key drivers
(four in AAW and three in liver) with diverse functions, including
transmembrane signaling (Figure 3E). The second RGN was
smaller (n = 44 genes) and active across all tissues except liver
(Figure 3F). Besides the Chr9p21 risk locus GWA gene
CDKN2A (Welter et al., 2014) in VF, it had three additional VF
key drivers: CLDN4, CTNNAL1, and MYSM1. The third multi-
tissue RGN (n = 37 genes), dominated by SF and AAW genes
(n = 12 and 22, respectively), was linked to HbA1c levels and
enriched in associations with CAD (4.1-fold, p < 3.4 3 1016),
HbA1c levels (3.3-fold, p < 6.8 3 1010), and insulin levels
(3.0-fold, p < 1.8 3 108) (Figure 3G). This RGN had three
key drivers (CLEC12A, CTSS, and FOLR3) implicated in cell
adhesion, cell-cell signaling, glycoprotein turnover, inflamma-
tion, and immune responses (e.g., antigen presentation). The
RGNs of the remaining 22 CAD-causal cholesterol, glucose,
and CRP modules (Figure 2B; Table S2) are shown in Figures
S2–S5; the characteristics and directions of gene-gene interac-
tions of the remaining RGNs inferred from all 171 modules are
described in Tables S5 and S6.
The CAD GWA genes (Brænne et al., 2015) were included as
regulatory priors in the RGN inference. However, compared to
eQTLs and transcription factors, their role as transcriptional
regulators can be debated. Of 25 GWA genes in 17 of the 30
CAD-casual modules, 13 were identified as key driver genes.
To test whether the RGN topology and the identification of the
non-GWA key drivers were dependent on including GWA genes
as regulatory priors, we repeated the RGN inference without
these; 16 RGNs were re-identified and contained, on average,
89% of the same edges and 91% of the same non-GWA key
drivers (Supplemental Experimental Procedures).
Cross-Species Validation of CAD-Causal RGNs
Examples of the successful use of mouse models to study
atherosclerosis in relation to plasma levels of cholesterol (Bjo¨r-
kegren et al., 2014; Skogsberg et al., 2008), glucose (Guo,
2014), and CRP (Kovacs et al., 2007) are many, suggesting
that some vascular and metabolic processes leading to CAD/
atherosclerosis are shared with humans. This might be particu-
larly true for RGNs thought to be well conserved throughout
evolution (Hinman et al., 2003). Therefore, in the next step of
the pipeline (Figures 1F and S1), we tested the phenotypic asso-
ciations of 26 of the 30 CAD-causal RGNs (Figures 3, S2, S3, and200 Cell Systems 2, 196–208, March 23, 2016 ª2016 The AuthorsS5) against the HMDP (Bennett et al., 2010); the four CRP RGNs
(Figure S4) were not validated, as CRP was not assessed in
the HMDP.
The HMDP consists of up to 105 different strains of mice with
considerable phenotypic variation and global gene expression
from relevant tissues—such as aortic atherosclerotic lesions,
liver, heart (used for STAGE SM), and adipose tissue—as well
as phenotypic characteristics, similar to the STAGE study (Sup-
plemental Experimental Procedures). In examiningmouse ortho-
logs of the 26CAD-causal RGNgenes (Table 1),we found that the
activity in three of seven CAD-causal, atherosclerosis-specific
modules (Figures 3D–3F) also segregated the 105 strains of
mice according to their extent of atherosclerosis. Similarly, three
of ten cholesterol-specificmodules (Figures S2C, S2D, and S2F),
three of five glucose-specific modules (Figures S3A, S3C, and
S3E), and at least one phenotype in three modules associated
with multiple phenotypes (Figure S5) also segregated the 105
miceof theHMDPaccording to thecorrespondingmousepheno-
types (Table 1). Thus, 46% (12/26) of the CAD-causal RGNs/
modules were related to corresponding phenotypes in mice.
In addition, we used aortic root lesion eQTLs and SNP p values
from a GWAS of the extent of aortic root lesions in the HMDP
(Supplemental Experimental Procedures) to assess the extent
to which the three cross-species-validated, atherosclerosis-
specificmodules (Figures 3D–3F) also were causal for themouse
atherosclerosis phenotype. The mouse eQTLs of orthologs of
genes in RGN 42 (Figure 3D), but not in RGN 58 (0.2-fold, p =
not applicable) and RGN 98 (0.0-fold, p = not applicable) (Figures
3E and 3F), were highly enriched in association with mouse
atherosclerosis (2.5-fold, p < 4.3 3 1084) and, thus, causal for
mouse atherosclerosis.
The Role of Cross-Species-Validated Atherosclerosis
RGNs in THP-1 Foam Cells
Foam cells form continuously throughout all stages of athero-
sclerosis development (Lusis, 2000) and, thus, may be affected
by CAD-causal RGNs related to the extent of human and mouse
atherosclerosis. Accordingly, in the final step of our analysis (Fig-
ures 1G and S1), we used differential gene expression and
cholesterol-ester accumulation measures (Supplemental Exper-
imental Procedures) to examine the effects of small interfering
RNA (siRNA) silencing of key drivers in the three cross-spe-
cies-validated CAD-causal atherosclerosis-related RGNs (Fig-
ures 3D–3F; modules 42, 58, and 98 in Table S2) in an in vitro
model of atherosclerosis. THP-1 cells differentiated into macro-
phages and incubated with acetylated LDL to generate foam
cells (Skogsberg et al., 2008). In RGN 42, which is enriched in
RNA-processing genes (Figure 3D), individual silencing of four
of seven key drivers (AIP, DRAP1, POLR2I, and PQBP1) specif-
ically activated RGN 42 network genes in THP-1 macrophages
and reduced cholesterol-ester accumulation in THP-1 foam cells
(Table 2). In contrast, silencing of key drivers in RGNs 58 and 98
did not specifically activate genes in these RGNs (Supplemental
Experimental Procedures; Table S7).
Re-identification of RGN 42 in Independent Gene
Expression Data
Since RGN 42 was the sole RGN to emerge from the analysis
pipeline (Figures 1A–1G and S1), we used independent gene
(legend on next page)
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Table 1. RGNModules Causally Related to CAD Segregating the STAGE Patients and up to 105 Strains ofMice of the HMDPAccording
to Similar Phenotypes
Module ID STAGE Phenotype STAGE Tissue
STAGE Combined
p Value HMDP Phenotype HMDP Tissue
HMDP Combined
p Value
Atherosclerosis modules
42 (Figure 3D) coronary atherosclerosis AAW 0.006 atherosclerosis aorta 0.01
58 (Figure 3E) coronary atherosclerosis AAW 0.001 atherosclerosis aorta 0.0007
98 (Figure 3F) coronary atherosclerosis AAW 0.03 atherosclerosis aorta 0.005
Cholesterol modules
87 (Figure S2C) plasma-cholesterol SF 0.01 LDL/TC adipose 0.008
95 (Figure S2D) HDL cholesterol VF 0.002 LDL cholesterol adipose 0.009
100 (Figure S2F) HDL cholesterol SF 0.006 LDL cholesterol adipose 0.0002
Glucose modules
64 (Figure S3A) pro-insulin SF 7.0 3 1005 insulin adipose 0.02
112 (Figure S3C) pro-insulin liver 0.0007 glucose liver 0.001
140 (Figure S3E) blood insulin SF 2.0 3 1005 insulin adipose 0.009
Multi-phenotype modules
27 (Figure S5A) LDL cholesterol SF 0.006 LDL cholesterol adipose 0.0001
36 (Figure S5B) plasma-cholesterol SM 5.0 3 1008 TC heart 0.02
105 (Figure S5C) blood insulin SF 8.0 3 1005 insulin adipose 0.02
AAW expression of mouse orthologs for genes in the STAGE atherosclerosis modules were tested against the extent of aortic root lesions in up to 105
strains of mice cross-bred with the ApoELeiden transgenic pro-atherogenic mouse model. Adipose tissue, heart, and liver expression of orthologs of
genes in the STAGE cholesterol and glucosemodules were tested against corresponding phenotypes in up to 105 strains of wild-typemice. The extent
of human coronary atherosclerosis was assessed from coronary angiograms; mouse atherosclerosis was assessed by Oil-Red-O staining of the aortic
roots. The p values are combined from second-step clustering and eigengene module correlations in both STAGE and HMDP (Supplemental Exper-
imental Procedures).expression datasets to examine the extent to which it could be
re-identified in the following: (1) in-house global gene expression
datasets from primary blood macrophage samples (n = 36) and
carotid lesions (n = 25) isolated from patients before and during
carotid surgery, respectively (Ha¨gg et al., 2009); and (2) datasets
generated by others from lipopolysaccharide-stimulated mono-
cytes (n = 18) and macrophages (n = 18) from CAD patients
(Schirmer et al., 2009). Reassuringly, the 109 genes in RGN 42
were more strongly co-expressed than sets of 109 random
genes, especially in the carotid lesions (9.5-fold higher con-
nectivity of RGN 42 genes than of genes in 10,000 random
sets, p < 1.0 3 10300) and also in macrophages (3.7-fold,
p = 6.2 3 10-37) (Ha¨gg et al., 2009), CAD lipopolysaccharide-
stimulated monocytes (2.2-fold, p = 1.1 3 1013), and CAD
macrophages (2.0-fold, p = 1.1 3 1011(Schirmer et al., 2009;
Supplemental Experimental Procedures).
CAD-Causal Arterial Wall RGNs and Gene Connectivity
Finally, we analyzed the CAD phenotype-associated modules
outside the main analysis pipeline (Figures 1A–1G and S1).
First, we utilized a unique feature of the STAGE cohort, a nearly
atherosclerosis-free arterial wall sample (i.e., IMA), as an inter-
nal control for the AAW. When molecular networks reflectingFigure 3. CAD-Causal RGNs Associated with Coronary Atherosclerosi
(A–H) Bayesian RGNs with key drivers inferred (Experimental Procedures) from C
candidate genes) linked to extent of coronary atherosclerosis. Fold enrichme
CARDIoGRAM dataset. The molecular process with the strongest functional enr
total and CAD candidate genes identified in GWASs of CAD, plasma lipid/glucos
202 Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authorsphysiological events are challenged with the effects of genetic
and environmental disease perturbations, gene-gene connec-
tivity increases for disease-relevant processes (Zhang et al.,
2013). Accordingly, to look for changes in connectivity in the
STAGE modules, we compared AAW (disease) and IMA
(healthy).
For the 13 AAW/IMA-specific or dominantmodules associated
with CAD phenotypes (Figure 2B), we calculated the gain/loss in
module connectivity (Figure 4). Interestingly, all five arterial wall
modules with >2-fold increases in connectivity also were CAD
causal (Figure 4). Of the eight arterial wall modules with <2-fold
increases in connectivity (seven AAW and one IMA), only two
were CAD causal (both in AAW). In both of these, gene connec-
tivity was already high in IMA (e.g., module 42, Figure 4). Thus,
CAD-causal modules appear to be characterized by high or
increased connectivity, whereas CAD-reactive modules either
do not change or lose connectivity in the arterial wall as CAD
develops.
To identify potential causes of the connectivity differences,
we analyzed cell type enrichment and transcription factor-bind-
ing site enrichment (Roider et al., 2009) for the sevenCAD-causal
modules with >2-fold increases in connectivity (modules 20, 37,
42, 58, 69, 133, and 138) (Figure 4). For the cell type enrichment,s
AD-causal modules (i.e., module eQTLs are risk enriched or contain CAD GWA
nt for CAD association was assessed for network eQTLs/SNPs using the
ichment assessed by gene ontology is indicated. KD, key driver; GWA genes,
e levels, and type 2 diabetes.
Table 2. Effects of siRNA Targeting of the AAW Key Drivers in RGN Module 42 (Figure 3D) on Network Gene Activity and Cholesterol-
Ester Accumulation in THP-1 Macrophages
Key Drivers in
Module 42
Effects of siRNA Inhibition of Key Drivers on Network Genes (n = 109)
in THP-1 Macrophages
Effects of siRNA Inhibition of Key Drivers on
CE Accumulation in THP-1 Foam Cells
Total Affected
Genes
Hyper-geometric
Test
Total Affected
Genes
Hyper-geometric
Test
Control
(Relative
CE Levels)
siRNA
(Relative
CE Levels)
CE Content
(% Relative
Control) p ValueNominal p Value <0.05 FDR < 10%
POLR2I 62 2.2 3 1006 59 1.0 3 1006 100 ± 48a 38 ± 24a 62 0.001
PQBP1 41 0.0002 24 0.002 100 ± 15a 69 ± 11a 31 7.0 3 1005
AIP 25 0.0005 9 0.003 100 ± 15a 149 ± 81a +49 0.02
DRAP1 32 0.003 12 0.02 100 ± 15a 70 ± 17a 30 0.0007
MRPL28 15 0.03 1 0.44 – – – –
PCBD1 13 0.03 0 1.0 – – – –
ZNF91 24 0.07 0 1.0 – – – –
All siRNA experiments achieved >80% gene silencing except for POLR2I (>50%). CE, cholesterol ester; FDR, false discovery rate; –, not tested.
aValues are mean ± SD.we examined 321 of 409 genes with matches in CTen (Shoe-
maker et al., 2012) that were responsible for the increased con-
nectivity in these top five modules. CD14-positive monocytes
stood out with an enrichment score of 65 (CD33-positivemyeloid
cells had the second highest enrichment score, 49), suggesting
that connectivity is increased by the infiltration and possibly dif-
ferentiation of circulating monocytes into/in the atherosclerotic
plaque.
For the transcription factor-binding site enrichment, genes in
module 58were enriched for binding sites ofMEF2A, a transcrip-
tional activator implicated in CAD (Bhagavatula et al., 2004;
Wang et al., 2013). Interestingly, among MEF2A’s target genes
were the first (CLEC2D) and fifth (CCRN4L) order key drivers in
module 58; CCRN4L has been linked to cardiovascular diseases
(Binns et al., 2009).
A Super-Network of 30 CAD-Causal RGNs
The second analysis we performed outside the main pipeline
(Figures 1A–1G and S1) was to identify a super-network of the
30 CAD-causal RGNs/modules by calculating the correlation
values between the module eigengenes (Supplemental Experi-
mental Procedures; Langfelder and Horvath, 2007). We found
that all 30 CAD-causal RGNs/modules were interconnected
and together formed a super-network connected across all
seven tissues (r > 0.4, p < 0.05, Figure 5). Within this super
network, SF dominated with 13 modules, AAW with seven, and
SM and VF with four modules each; notably, blood and liver
had only one CAD-causal module each. Ninemodules were con-
nected only within a given tissue as follows: modules 14, 23, 148,
and 152 in SF; module 8 in VF; modules 89 and 99 in SM; and
modules 69 and 133 in AAW (Figure 5). In contrast, the cross-tis-
sue modules 98 (dominated by VF genes including its key
drivers) and 113 (dominated by SF genes including its key
drivers) appeared to act as hub modules, mediating all but one
(module 27 in SF) connection from SM and liver (module 98)
and from SF (module 113) to the AAW (none of the CAD-causal
modules were identified in the IMA).
The notion that cross-tissue modules can serve as hubs in this
super-network of CAD-causal modules was reinforced by the
greater and stronger connectivity in the super-network ofcross-tissue modules than of tissue-specific modules (mean
number of connections: 5.33 ± 1.73 versus 3.43 ± 2.04, p <
0.02; mean connectivity strength: 2.96 ± 0.98 versus 1.98 ±
1.20, p < 0.03). Notably, module 98 contained genes involved
in endopeptidase activity (Table S3) previously implicated in
atherosclerosis (Kugiyama et al., 1996), and one of its four key
drivers, CDKN2A, is a CAD candidate gene for the Chr9p21
risk locus (Welter et al., 2014; Table S2). Interestingly, the allelic
variation of the Chr9p21 risk SNP (rs4977574) was associated
with increased connectivity of the VF genes in module 98 (risk
genotype G/G, n = 20 STAGE patients; mean connectivity ±
SD, 2.34 ± 1.01), the non-risk heterozygotes (A/G, n = 47 STAGE
patients, mean connectivity 1.37 ± 0.33); and the non-risk homo-
zygotes (A/A, n = 21 STAGE patients, mean connectivity 1.43 ±
0.34) (p = 0.002, Kruskal-Wallis test).
DISCUSSION
In this study, we used systems genetics integrating the analysis
of (1) DNA genotypes and gene expression profiles in seven
CAD-relevant tissues from CAD patients (STAGE cohort) and
(2) CAD GWA datasets (primarily Coronary Artery Disease
Genome-wide Replication and Meta-analysis [CARDIoGRAM]).
Our findings provide a preliminary view of the regulatory land-
scape of causal molecular processes active within and across
a majority of tissues believed to be central to advanced CAD.
The identified RGNs included both established (Brænne et al.,
2015) and previously unreported CAD candidate genes in the
form of key drivers. These candidate genes participate in diverse
molecular processes and established pathways of athero-
sclerosis, cholesterol and glucose metabolism, and acute
inflammation, and they were regulated in both tissue-specific
and cross-tissue networks. Importantly, we found that nearly
half of the RGNs (where similar mouse phenotypes were avail-
able, 12/26, 46%) were evolutionarily conserved, as judged
from validation against the HMDP (Bennett et al., 2010). As proof
of concept, in one cross-species-validated, mouse atheroscle-
rosis- and CAD-causal network active in AAW and involving
RNA-processing genes, four key drivers (AIP, DRAP1, POLR2I,
and PQBP1) specifically activated the same network genesCell Systems 2, 196–208, March 23, 2016 ª2016 The Authors 203
and affected THP-1 foam cell formation, and the entire network
also was re-identified in independent gene expression data from
both CAD macrophages and carotid lesions.
It is increasingly recognized that to defeat complex diseases
like CAD it is not sufficient to focus on individual DNA variants
or CAD candidate genes. In parallel, we need to use systems ge-
netics to understand how these disease genes operate in com-
plex regulatory networks (Schadt, 2009). In examining the 171
RGNs inferred from all STAGE modules (Figures 3 and S2–S5;
Tables S5 and S6) in greater detail, we found a good representa-
tion of established genes, pathways, and molecular functions in
CAD. For instance, these modules contained 147 of the 309
GWA genes thus far proposed for CAD and CAD risk factors,
such as lipid and glucose metabolism, including type 2 diabetes
(Table S4). Thus, our results should be useful in gaining a better
understanding of the tissue-specific or cross-tissue molecular
contexts of established CAD candidate genes identified by
GWASs. Our results will be particularly useful in providing clues
about their upstream regulations by key disease drivers, which
frequently were not the GWA genes themselves.
Although it is vital to identify individual CAD candidate genes in
the context of regulatory networks, RGNs do not act in isolation
but interact. Indeed, we identified a super-network containing all
30 CAD-causal RGNs across all the main CAD tissues. The tis-
sue distribution of RGN interactions is significant, as it links a
good portion of disease-driving molecular processes in CAD,
including their relation to key metabolic risk factors (e.g., choles-
terol and glucose metabolism), and it provides a preliminary
overview of the gene regulatory landscape in CAD. Mapping
the regulatory framework of complex diseases in this fashion
provides a starting point to assess the overall molecular status
of individual patients (Bjo¨rkegren et al., 2015). In fact, more
detailed versions of regulatory maps like the one presented
here (Figure 5) are required to achieve the goals of precision
medicine.
Notably, most of the CAD-causal RGNs in this super-network
were active in nonhepatic peripheral organs, particularly SF (Fig-
ure 5); only one was in the liver. The paucity of hepatic modules/
RGNs and the unexpectedly high number of fat modules/RGNs
may be consistent with the emerging notion that key hepatic pro-
cesses in cardiometabolic diseases are governed by metabolic
processes and gene expression activity in nonhepatic peripheral
tissues (Lomonaco et al., 2012). In fact, the connectivity map of
the super-network of CAD-causal modules suggests that causal
effects of metabolic processes in the SM and liver on the CAD-
causal modules of the AAW are largely mediated by a single
cross-tissue RGN primarily active in VF. This RGN also was
found to contain CDKN2A, a candidate gene for the well-estab-
lished Chr9p21 CAD risk locus, as one of its four key drivers (Fig-
ure 5). Moreover, the connectivity of this RGN was found to be
associated with the allele frequency of the Chr9p21 CAD risk lo-
cus. Similarly, effects on the CAD-causal modules of the AAW of
the many RGNs identified in SF also were predominantly medi-
ated by one cross-tissue module (Figure 5).
Although a systems genetics approach has the significant
advantage of simultaneously considering many genes (i.e.,
RGNs) in relation to disease, there are also challenges (Civelek
and Lusis, 2014). In brief, cell diversity in the tissue biopsies
can be a problem, as changes in gene activity also will reflect204 Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authorschanges in cell type content. Furthermore, the inference of
causal (i.e., directed) RGNs from omics data can be hampered
by data noise, limited sample size, and the inherent limitations
of representing complex biological processes by statistical
models, which inevitably leads to false positives even among
the most significant predictions (Marbach et al., 2010). Thus,
as with gene-by-gene approaches, RGNs inferred from genetics
of gene expression studies must be examined and validated
extensively.
To this point, we validated three atherosclerosis-related RGNs
using an in vitromodel of atherosclerosis (Skogsberg et al., 2008;
Figures 1 and S1, StepG). Silencing of the key drivers of RGN 42,
AIP, DRAP1, POLR2I, and PQBP1, which involve RNA process-
ing, specifically reactivated RGN 42 genes in THP-1 macro-
phages and affected cholesterol-ester accumulation (i.e., foam
cell formation) (Table 2). Although none of these four key drivers
have been directly linked to CAD, atherosclerosis, or foam cell
formation, AIP affects the expression of peroxisome prolifera-
tor-activated receptors a and b (Sumanasekera et al., 2003a,
2003b) and, thus, may prevent foam cell formation via the
HDL/ABCA1 pathway (Chinetti et al., 2001) or the CD36 scav-
enger receptor pathway (Li et al., 2004). Similarly, DRAP1 re-
presses TGF-b signaling by interfering with the binding of
FoxH1-Smad2/3/4 to its DNA targets during transcription (Iratni
et al., 2002). TGF-b signaling prevents foam cell formation by
activating ABC1 and reverse cholesterol transport (Kozaki
et al., 1997). POLR2I and PQBP1, however, have not even
been indirectly associated with atherosclerosis or foam cell for-
mation, returning only 93 and 69 hits, respectively, in PubMed.
POLR2I encodes a subunit of RNA polymerase II, the polymer-
ase responsible for synthesizing mRNA in eukaryotes and also
targeted by HIV-1 during lytic and latent viral stages (Nilson
and Price, 2011). PQBP1 is a key regulator of mRNA processing
and gene transcription. In fact, mutations in PQBP1 have been
reported in several X chromosome-linked intellectual disability
disorders, including Golabi-Ito-Hall syndrome (Sudol et al.,
2012). PQBP1 also may be linked to fat metabolism (Takahashi
et al., 2009), and, as a splicing factor, it alters fibroblast growth
factor signaling (Wang et al., 2013). The fact that RGN 42 is
related to RNA processing may be significant in view of the
gene-regulatory roles of noncoding RNAs in general (Mihailescu,
2015) and in CAD (Bronze-da-Rocha, 2014).
In summary, our identification of several high-hierarchy, evolu-
tionarily conserved, strongly inherited risk-enriched, and repro-
ducible RGNs is a breakthrough in our understanding of the mo-
lecular landscape causing CAD across tissues. Specifically, we
have shown for the first time that RNA-processing genes appear
central in causing CAD. Key regulatory genes in this and other
RGNs may be proven useful as targets for novel CAD therapies.EXPERIMENTAL PROCEDURES
The STAGE Genetics of Gene Expression Study
In the STAGE study, 612 tissue samples were obtained during coronary artery
bypass grafting surgery from AAW (n = 73), IMA (n = 88), liver (n = 87), SM
(n = 89), SF (n = 72), and VF (n = 98) of well-characterized CAD patients
(Ha¨gg et al., 2009). Fasting whole blood was obtained for isolation of DNA
(n = 109) and RNA (n = 105) and biochemical analyses. RNA samples were
used for gene expression profiling with a custom Affymetrix array (HuRSTA-
2a520709). Blood DNA was genotyped for 909,622 SNPs with the Affymetrix
(legend on next page)
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Figure 5. A Super-Network of CAD-Causal Modules
Eigengene associations (r > 0.4, p < 0.05) were used to link the 30 CAD-causal modules (Experimental Procedures). RGNs/modules (circles) are oriented ac-
cording to dominating tissue-belonging of genes and are color coded accordingly. Numbers in circles are the module IDs. Circle size corresponds to the number
of RGN/module genes. Next to each box, the names of GWA genes in the RGNs/modules and related trait (in superscript) are indicated. TS, tissue-specific RGN/
module; CT, cross-tissue RGN/module; colored circle circumferences, phenotype associations; dotted lines, RGNs/modules that are reactive to indicated
phenotype; solid line, RGNs/modules that are causal for indicated phenotype (i.e., GWA gene[s] for the phenotype or eQTLs enriched with association for the
phenotype); orange, plasma cholesterol measures; blue, plasma glucose metabolism measures; purple, plasma CRP levels.GenomewideSNP_6 array. The carotid lesion and CAD macrophage gene
expression data were generated with the same custom Affymetrix arrays
mentioned above (Shang et al., 2014).
Multi-tissueWeightedGeneCo-expressionNetwork Reconstruction
WGCNA (Zhang and Horvath, 2005) was used to identify co-expression
network modules that simultaneously captured gene-gene relations within
and across tissues (Table S8), using the following most variably expressed
genes (SD > 0.5 across samples): 3,369 in AAW; 2,761 in IMA; 1,588 in liver;
2,492 in SM; 3,596 in SF; 5,215 in VF; and 1,891 in blood. In WGCNA, values
of b = 6 and b = 3 were used to weigh within-tissue and across-tissue correla-
tions, respectively, to ensure that both tissue-specific and cross-tissue sub-
networks, as well as whole networks, were scale free.
Associations of Modules and CAD Phenotypes
Module associations with four main CAD phenotypes (Results) were tested as
follows: (1) by a rank-sum test of the mean phenotype values of the two most
distinct patient subsets, defined by clustering the gene activity within eachFigure 4. Differential Connectivity in Arterial Wall Modules with and wi
Differential connectivity plots for AAW- and IMA-dominant, phenotype-associa
between all pairs of module genes in IMA (lower triangle) and AAW (upper tria
connectivity (MDC) (ratios of sum of connectivity values in AAW to IMA). Red b
MDC values >1 correspond to modules with a gain of connectivity in AAW versu
206 Cell Systems 2, 196–208, March 23, 2016 ª2016 The Authorsmodule; and (2) by calculating Pearson correlations between phenotype and
module eigengene values (Langfelder and Horvath, 2007). Integrated p values
from both tests and from multiple measurements for each main phenotype
(e.g., TC, LDL, VLDL, and HDL for plasma cholesterol levels) were computed
with a weighted data integration method (Hwang et al., 2005) and corrected
for multiple testing by estimating a false discovery rate (FDR < 0.2) (Storey,
2002).
eQTL Enrichment for Risk Associations and CAD Candidate Genes
According to GWASs
To examine the extent to which modules were CAD causal, we used enrich-
ment in inherited CAD association or GWAS candidate genes (Deloukas
et al., 2013). In brief, disease assocations of cis-eQTLs detected in the STAGE
patients (or, if the number of cis-eQTLs was less than ten, SNPs located
within ±500 kb of the transcription start or end site of each module gene)
were used to calculate fold enrichment and statistical significance compared
to 10,000 random SNP groups corrected for chromosome, gene density, and
major allele frequency (Foroughi Asl et al., 2015). CAD candidate genes (n = 53)thout Atherosclerosis
ted modules. Each plot shows the adjacency values (weighted correlations)
ngle). Modules are sorted from high to low according to module differential
ars indicate CAD-causal modules. Green bars indicate non-causal modules.
s IMA.
were obtained from CARDIoGRAM. Similarly eQTL disease associations and
additional GWA candidate genes for CAD risk factors were computed using
additional GWASs (Supplemental Experimental Procedures) and data from
the HMDP.
RGN Reconstruction
Gaussian Bayesian networks were reconstructed for each module by
imposing a prior that only genes with eQTLs, transcription factors, or CAD
GWA genes could be parents of other genes. The Bayesian Information Crite-
rion (BIC) was used to score models; a multiple-restart greedy hill-climbing al-
gorithm, with edge additions, deletions, and reversals, was used to search
locally optimal models (Schmidt et al., 2007).
Key Driver Analysis and Validation
Key drivers were identified from the Bayesian networks as described previ-
ously (Zhang and Zhu, 2013), and they were validated by siRNA silencing in
THP-1 macrophages incubated with Ac-LDL to induce foam cell formation
(Table S9), as described previously (Skogsberg et al., 2008). Gene expression
data from siRNA-treated and control THP-1 cells were generated by Agilent
Human Custom Gene Expression Microarray 8315 and compared to assess
the effect of a key driver on its RGN, as described previously (Bjo¨rkegren
et al., 2014).
Mouse Phenotype Associations
To validate the phenotype associations of CAD-causal modules, we assessed
the association of ortholog genes in corresponding mouse tissues and pheno-
types in the HMDP (Bennett et al., 2010), using the same methods described.
Module Connectivity and Differential Connectivity
Total module connectivity was calculated as the sum of adjacency values (i.e.,
weighted correlation coefficients) between all pairs of genes in amodule. Mod-
ule differential connectivity between AAW and IMA was calculated as the ratio
of total module connectivity in AAW to total module connectivity in IMA.
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